MBX Biosciences Quarterly Cash Flow Statement
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
53.24-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences free cash flow
In the quarter ended Jun 30, 2026, MBX Biosciences generated -$22.6 million of operating cash flow and spent $901,000 on capital expenditures. That left free cash flow of -$23.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -37.09M | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M | -10.16M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 100.00K | 64.00K | 60.00K | 100.00K | 100.00K | 77.00K | 58.00K | 100.00K | 100.00K | 48.00K | 41.00K | 100.00K |
| Stock-Based Compensation | 6.06M | 5.48M | 2.66M | 2.25M | 1.94M | 1.84M | 1.49M | 1.19M | 919.00K | 1.62M | 1.02M | — |
| Change in Working Capital | 8.01M | -928.00K | 1.59M | -1.55M | 1.19M | -1.01M | -587.00K | 2.81M | 2.06M | 471.00K | -2.81M | — |
| Operating Cash Flow | -22.62M | -20.21M | -18.30M | -21.54M | -17.43M | -22.68M | -16.04M | -14.66M | -13.27M | -10.71M | -11.15M | — |
| Capital Expenditures | -901.00K | -437.00K | -793.00K | -399.00K | -707.00K | -30.00K | -92.00K | -57.00K | -452.00K | -273.00K | -55.00K | — |
| Investing Cash Flow | 29.21M | -97.10M | -129.97M | 17.06M | 25.99M | 3.23M | -67.34M | -100.79M | -7.89M | 15.43M | -28.95M | — |
| Financing Cash Flow | 2.32M | 87.44M | 438.00K | 187.82M | 1.33M | 4.00K | -132.00K | 235.81M | -1.76M | 183.00K | 19.00K | — |
| Net Change in Cash | 8.91M | -29.87M | -147.84M | 183.34M | 9.88M | -19.45M | -83.51M | 120.36M | -22.92M | 4.90M | -40.08M | — |
| Free Cash Flow | -23.52M | -20.64M | -19.09M | -21.93M | -18.14M | -22.71M | -16.13M | -14.72M | -13.72M | -10.98M | -11.20M | — |
This table shows 12 quarterly periods of MBX Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a cash flow statement?